Table 1.
Clinical characteristics of RCC patients.
| Patient ID | Age | Gender | Pathological diagnosis | Furman grade | TNM stage | Treatment | Months of treatment | Relapse | Relapse time after treatment(month) | Best response |
|---|---|---|---|---|---|---|---|---|---|---|
| 01 | 54 | M | ccRCC | Ⅲ | T2N0M1 | sorafenib | 5 | Y | 5 | PD |
| 02 | 63 | F | ccRCC | Ⅱ | T2N0M1 | sorafenib | 7 | Y | 7 | PD |
| 03 | 47 | M | ccRCC | Ⅱ | T2N0M1 | sorafenib | 8 | Y | 8 | PD |
| 04 | 67 | M | ccRCC | Ⅲ | T3N1M1 | sorafenib | 5 | Y | 5 | PD |
| 05 | 54 | F | ccRCC | Ⅱ | T2N0M1 | sorafenib | 3 | Y | 3 | PD |
| 06 | 49 | F | ccRCC | Ⅲ | T3N1M1 | sorafenib | 5 | Y | 3 | PD |
| 07 | 63 | M | ccRCC | Ⅱ | T2N0M1 | sorafenib | 4 | Y | 5 | PD |
| 08 | 55 | M | ccRCC | Ⅱ-Ⅲ | T3N0M1 | sorafenib | 16 | N | - | PR |
| 09 | 69 | F | ccRCC | Ⅱ | T2N1M1 | sorafenib | 13 | N | - | PR |
| 10 | 43 | M | ccRCC | Ⅲ | T2N0M1 | sorafenib | 12 | N | - | PR |
| 11 | 47 | M | ccRCC | Ⅲ | T2N0M1 | sorafenib | 14 | N | - | PR |
| 12 | 58 | F | ccRCC | Ⅱ-Ⅲ | T3N0M1 | sorafenib | 11 | N | - | PR |
| 13 | 54 | F | ccRCC | Ⅲ | T2N0M1 | sorafenib | 11 | N | - | PR |
| 14 | 63 | M | ccRCC | Ⅲ | T2N1M1 | sorafenib | 13 | N | - | PR |
| 15 | 52 | M | ccRCC | Ⅱ | T2N0M1 | sorafenib | 16 | N | - | PR |